Veradermics Reports Success in Hair Loss Drug Trial

The drug candidate VDPHL01 showed significant hair regrowth in men during a recent Phase 3 clinical study.

Updated on Oct. 20, 2026 in Men’s Health

Veradermics Reports Success in Hair Loss Drug Trial

Live Poll

Would you consider using new pharmaceutical treatments for hair loss if they become available?

Veradermics has announced positive topline results from a Phase 3 study for its oral extended-release minoxidil drug candidate, VDPHL01. The treatment demonstrated measurable hair count increases in men with mild to moderate pattern hair loss over a six-month period.

Why it matters

The company aims to address limitations of existing minoxidil formulations, specifically regarding hair regrowth potential and cardiac toxicity risks. This successful trial brings a new treatment option closer to the competitive hair loss market.

Participants taking the drug twice daily reported an 85% hair coverage improvement, compared to 35.3% in the placebo group. The two phase 3 trials included a total of 700 men, with no recorded cardiac adverse events reported.

The players

Veradermics

Veradermics is a biotechnology company focused on developing pharmaceutical treatments for hair loss and related conditions.

Food and Drug Administration

The Food and Drug Administration is the federal agency responsible for regulating pharmaceutical products and safety in the United States.

The details

The study involved over 500 men who took the oral treatment once or twice daily for six months to evaluate regrowth using the target area hair count metric. The research also utilized the self-reported Androgenetic Alopecia Impact Rating Scale to gauge patient-perceived improvements in hair coverage.

1979: Oral minoxidil received original FDA approval for low blood pressure treatment.
February 2026: Veradermics share price began an upward trend.
October 19, 2026: Veradermics released the topline results for study 304.

Health Landscape

This development represents an evolution of existing cardiovascular-derived treatments, moving from generic blood pressure medication to specialized hair loss therapy. It highlights a shift toward addressing historical toxicity concerns associated with systemic minoxidil use.

Patients may eventually gain access to an oral treatment designed to offer better hair regrowth potential than existing options while minimizing cardiac risks. Final availability will depend on the upcoming regulatory review process.

The takeaway

This trial success provides a potential new alternative for individuals seeking non-topical solutions for pattern hair loss. Consumers should continue to consult with healthcare providers regarding the safety profile of any new hair loss medication.